AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04806191 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Usual care as provided by the GP
Study NCT06119061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin Injection
Description: Telavancin 10mg/kg (maximum 1000mg) administered intravenously over 60 minutes (through a central venous catheter whenever available).
Study NCT05116904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment
Description: Pupil reflex and melatonin profile, circadian profile assessment
Study NCT06550960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of two biopsy systems
Description: Each subject will have prostate biopsy taken in 6 locations in one lobe of the prostate and then biopsy in 6 locations in the other lobe of the prostate
Study NCT06550960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evaluation of two biopsy systems
Description: Each subject will have prostate biopsy taken in 6 locations in one lobe of the prostate and then biopsy in 6 locations in the other lobe of the prostate
Study NCT05670561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: PCIA formula#100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously.No obvious adverse reactions were observed for 10min. The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
Study NCT06459336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive constraint-induced movement therapy
Description: Intensive protocol of CIMT will be given for 6hrs for 6 days to make total of 36 hours
Study NCT06459336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distributed constraint-induced movement therapy
Description: Distributed protocol of CIMT will be given for 2.25hrs two times a week for 8 weeks making total of 36 hours
Study NCT04706000 — intervention group
Intervention type: GENETIC
Intervention: Beclin 1 gene
Description: The determination of Beclin 1, LC3-II and p62 genes, which are evaluated by immunohistochemistry, at the protein level will be done by ELISA method in MSKU Medical Faculty Medical Biology Laboratory.
Study NCT06228586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine
Description: Pharmaceutical form:Liquid solution-Route of administration:Intramuscular injection
Study NCT05462197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong Wuqinxi
Description: Wuqinxi is an exercise method developed by the ancient Chinese physician Hua Tuo by combining the ancient guide, breathing, and imitating the shapes of five animals, such as tiger, deer, bear, ape, and bird, combined with the zang-fu and meridian theory of traditional Chinese medicine. There have been studies in the past proven that this exercise can achieve health-promoting effects
Study NCT05643261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle and technique training
Description: The strength training consists of three exercises (clam shell, side plank, calf raises) with an progressive overload after two to three weeks to ensure a continuous muscle stimulation. The technique training consists of different cutting variations with a focus on forefoot landings and conscious control of the knee to avoid high knee valgus movement and KAM respectively.
Study NCT05796011 — intervention group
Intervention type: DEVICE
Intervention: hearing aids
Description: Hearing aid(s) fitted for one or two sides of ear.
Study NCT05796011 — intervention group
Intervention type: OTHER
Intervention: without hearing intervention
Description: neither earing aids nor other heaing treatment were applied.
Study NCT05796011 — intervention group
Intervention type: OTHER
Intervention: healthy control
Description: healthy control
Study NCT06421727 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation by optokinetic stimulation and virtual reality exercises .
Description: Rehabilitation by optokinetic stimulation and virtual reality exercises(by deviceVirtual reality system(Meta Quest 2_Advanced All-In-One Virtual Reality Headset_ 128 GB)).
Study NCT06303011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulator
Description: TENS will be applied on sacral and parasacral area. Frequency 10Hz, Pulse duration 200μs, Stimulation duration 20min
Study NCT05463510 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Videodermoscopy
Description: Patients who had records for at least twice with videodermoscopy every 3 months were included.
Study NCT04896710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SD Biosensor
Description: Nasal swab SD biosensor to be self administered
Study NCT04665050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Study NCT04665050 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNEUMOVAX™23
Description: Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Study NCT05266092 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Observational study
Study NCT04716127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proximity-incentive strategy based on vaginal self-sampling for women 50 to 65 years who do not participate to cervical cancer screening
Description: * Direct offer of a vaginal self-sampling kit with information to perform at home and send back to the laboratory for HR-HPV testing~* The psychosocial determinants involved in decision-making process and compliance to cervical cancer screening will be collected from open questionnaires and by semi-directive phone interviews~* Control ; Receive reminder to send the self-sample to the laboratory : After 3 and 6 months without return, women receive a remind letter to send the vaginal self-sample to the laboratory. We call return the receipt of the vaginal self-sample at the laboratory.~* Control ; Receive reminder to perform cervical smear in case of positive HR-HPV test : In case of a positive HR-HPV test, women are asked to perform a control cervical smear. After 3, 6 months and 12 months without return, women and their health-care professional will receive a remind letter or a call to perform a cervical smear for control. We call return the performance of a pap smear.
Study NCT05004376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Text messages based on behavioral theory to encourage scheduling colorectal cancer screening.
Study NCT06328153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fu's Subcutaneous Needling
Description: Operation of the FSN will follow the KOA's Fu's Subcutaneous Needling Treatment Code of Practice24. After routine disinfection, a disposable Fu's subcutaneous needle ( Nanjing-Paifu Medical Technology Co., Ltd., Jiangsu, China ) is inserted parallel into the subcutaneous loose connective tissue of the pathological tight muscles ( gastrocnemius muscle, tibial anterior muscle and quadriceps femoris muscle ). The FSN needle is operated in a swaying movement. The fan angle is approximately 60°; perform a total of 45 round trips in 30 seconds. Swaying is accompanied by reperfusion approach: 20 sweeps with 10 seconds of reperfusion approach as a group, 3 groups for each pathological tight muscle. The reperfusion approach requires active, short and sharp contractions of the pathological tight muscle. The muscle alternates contraction and relaxation. The FSN group is treated 3 times a week for 2 weeks.
Study NCT06328153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Participants in the drug group will receive celecoxib (capsule) 200mg every day continuously for 2 weeks.
Study NCT04697693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: The participant will be begun on either escitalopram 10mg or duloxetine 30mg. Subjects will begin escitalopram 10mg, continue this dosage for 4 weeks, then if the HRSD >7 at Week 4, he/she will have their dosage increased to 20mg for the remainder of the 8 week study.
Study NCT06303011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS on para sacral area with Abdominal Massage
Description: TENS on para sacral area with Abdominal Massage. Frequency 10Hz Pulse duration 200μs Stimulation duration 20min
Study NCT04697693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Participants who have not responded to or not tolerated escitalopram in the current depressive episode will be started on duloxetine. They will take 30mg for the first 2 weeks, then, contingent on clinical assessment that the 30mg dose is sufficiently well tolerated, be increased to 60mg for the remaining 6 weeks of the study.
Study NCT05451979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedBIKE HIIT
Description: Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
Study NCT05298748 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Womb sound recordings
Description: Womb sounds will be chosen from commercially available (Amazon) womb recordings using a recording that most closely resembles the womb including maternal heart rate, fetal heartbeat, respiratory sounds, bowel popping sounds and frequency spectra as described by Parga, Daland 2018 et al.
Study NCT06151587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLM3004 Concentration 1
Description: Low dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime
Study NCT06151587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLM3004 Concentration 2
Description: Medium dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime
Study NCT05450380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFT001
Description: The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face.~The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face.
Study NCT06190080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Digestive endoscopy
Description: Digestive endoscopies are performed in the operative room under general anaesthetic 3 months after the introduction or change of treatment. Biopsies of the upper, middle and lower thirds of the esophagus will be taken and analyzed for pathology.
Study NCT05196685 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid Doppler USG
Description: All Doppler ultrasonography measurements will be made in a dimly lit room at room temperature, with the patient in the supine position, the head slightly hyperextended, the patient looking to the left when measuring the right side, and the patient looking to the right when measuring the left side. In all patients, common carotid artery (CCA), internal carotid artery (ICA) and vertebral artery (VA) gray scale and color Doppler ultrasonography wşll be performed using the GE 9L Linear Probe. Color Doppler examination will be performed with a frequency of 4.0/8.0 MHz.
Study NCT06372574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7617991
Description: RO7617991 will be administered by intravenous (IV) infusion. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Study NCT06372574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8 mg/kg IV will be administered to patients when necessary to treat potential cytokine release syndrome (CRS), as described in the protocol.
Study NCT05607862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Physiotherapy Group
Description: The intervention group will receive 2 sessions per week for 8 weeks supervised and assisted by a physiotherapist at the patient's home. Muscle strengthening exercises of the lower and upper limbs, stretching, coordination and balance exercises, gait re-education with the relevant technical aids, a pattern of exercises to be performed daily by the patient and health education guidelines will be carried out.
Study NCT05607862 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: The control group will be given health education guidelines and will continue with their usual medical-pharmacological treatment. All patients included in this study will receive physiotherapy treatment, and those in the control group will be treated once the intervention and the post-intervention assessment have been completed.
Study NCT05659563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)
Study NCT05659563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen is a selective estrogen receptor (ER) modulator
Study NCT06533930 — intervention group
Intervention type: OTHER
Intervention: Transorbital Sonography
Description: OND and ONSD of participants in the MS patient group and healthy control group were measured by TOS.
Study NCT06533930 — intervention group
Intervention type: OTHER
Intervention: Orbita Magnetic Resonance Imaging
Description: OND and ONSD of participants in the MS patient group were measured by orbita MRI.
Study NCT06533930 — intervention group
Intervention type: OTHER
Intervention: Visual Evoked Potentials
Description: P100 amplitude and P100 latency values of participants in the MS patient group were measured by VEP.
Study NCT06533930 — intervention group
Intervention type: OTHER
Intervention: Optical Coherence Tomography
Description: pRNFL thickness of participants in the MS patient group were measured by OCT.
Study NCT06151587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLM3004 Concentration 3
Description: High dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime
Study NCT06151587 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study NCT06557499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyurethane (PU) male condom-Test condom 1
Description: A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
Study NCT06557499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyurethane (PU) male condom-Test condom 2
Description: A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
Study NCT06557499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Natural Rubber Latex (NRL) male condom- Control condom
Description: A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
Study NCT04594876 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Flouroscopic guidance cervical epidural versus cervical facet injection
Description: The patients are classified in two groups group P for cervical epidural and group F for facet injection. The skin will be prepared with an antiseptic solution. The midline of the selected interspace will be identified under fluroscopic guidance.
Study NCT05733494 — intervention group
Intervention type: OTHER
Intervention: Administration of Clinical Assessment of Dysphagia in Neurodegeneration (CADN)
Description: the CADN will be administrated to each patient at the enrolment
Study NCT05513729 — intervention group
Intervention type: DRUG
Intervention: Canagliflozin
Description: According to the guideline of type 2 diabetes，canagliflozin will be given to 40 patients with type 2 diabetes combined with NAFLD as first-line choice if accompanied with indicators of high risk or established atherosclerotic cardiovascular disease, chronic kidney disease or heart failure, independently of HbA1c level. It can be also given to T2DM combined with NAFLD if their HbA1c above target.
Study NCT05513729 — intervention group
Intervention type: DRUG
Intervention: Pioglitazone
Description: According to the newest guideline of Diabetes，pioglitazone will be given to 40 patients with T2DM combined with NAFLD if their HbA1c above target.
Study NCT04561271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot reflexology
Description: Patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. A neutral oil will be used. The technique associates specific movements of foot reflexology. The session is accompanied by relaxing music.
Study NCT04561271 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: toucher massage
Description: one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
Study NCT05160909 — intervention group
Intervention type: PROCEDURE
Intervention: Beach Chair Position
Description: Patients positioned in beach chair during arthroscopic shoulder stabilization
Study NCT05160909 — intervention group
Intervention type: PROCEDURE
Intervention: Lateral Decubitus Position
Description: Patients positioned in lateral decubitus position during arthroscopic shoulder stabilization
Study NCT05223725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdKCNH2-G628S
Description: adenovirus containing the transgene KCNH2-G628S
Study NCT05015257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard F100
Description: 100 kcal and 3 g protein per 100 ml
Study NCT05015257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard F75 + Plumpynut
Description: Standard F75 with ready to-use therapeutic food (Plumpynut)
Study NCT05015257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alternative F75 with CMV + Plumpynut
Description: Alternative F75 containing CMV with ready to-use therapeutic food (Plumpynut)
Study NCT05015257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alternative F75 without CMV + Plumpynut
Description: Alternative F75 with no CMV with ready to-use therapeutic food (Plumpynut)
Study NCT04876430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Meropenem 2g every 8h for patients with glomerular filtration rate (GFR) equal or higher that 50 mL/min. Dose adjustment is recommended for patients with GFR \< 50mL/min.
Study NCT04500626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Hyperbaric oxygen therapy delivered in a monoplace or multi-place chamber. Supervised by a hyperbaric oxygen therapy physician and a chamber operator.
Study NCT05413148 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Subtenon injection of Wharton jelly derived mesenchymal stem cells
Description: Single subtenon's injection for single eye
Study NCT05413148 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes
Description: Single subtenon's injection for single eye
Study NCT05413148 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Subtenon injection of saline for a single eye
Study NCT05500430 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air abrasion sandblasting aluminum oxide particles (Al2O3) AquaCare single (Velopex, Medivance Instruments Ltd., London, UK)
Description: Air abrasion sandblasting aluminum oxide particles (Al2O3) Aqua Care single (London, UK) will be done for the defective area then repairing with bioactive injectable composite, Beautiful Flow Plus X F00 (Shofu, Japan).
Study NCT05500430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air abrasion sandblasting aluminum oxide particles (Al2O3) AquaCare single (Velopex, Medivance Instruments Ltd., London, UK)
Description: Air abrasion sandblasting aluminum oxide particles (Al2O3) Aqua Care single (London, UK) will be done for the defective area then repairing with bioactive injectable composite, Beautiful Flow Plus X F00 (Shofu, Japan).
Study NCT05961137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol
Description: Modified protocol specifying intravenous crystalloid infusion Rapid Fluid Infusion Device. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.